GDC-0339
GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma[1][2].
Product Specifications
CAS Number
1428569-85-0
UNSPSC
12352005
Target
Pim
Type
Reference compound
Related Pathways
JAK/STAT Signaling
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/GDC-0339.html
Concentration
10mM
Purity
99.87
Solubility
DMSO : ≥ 52 mg/mL
Smiles
FC1=CC=CC(F)=C1C2=NC(C(NC3=C(N4CC[C@@H](F)[C@H](N)CC4)N(C)N=C3)=O)=C(N)S2
Molecular Formula
C20H22F3N7OS
Molecular Weight
465.50
References & Citations
[1]Takahashi RH, et al. CYP1A1-Mediated Intramolecular Rearrangement of Aminoazepane in GDC-0339. Drug Metab Dispos. 2017 Oct;45 (10) :1084-1092.|[2]Wang X, et al. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. J Med Chem. 2019 Feb 28;62 (4) :2140-2153.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PIM1; PIM2; PIM3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC942550-500 1x 500 µL
NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/2550R), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 